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Abstract: The C-promoter binding factor-1 (CBF-1) is a potent and specific inhibitor of the human
immunodeficiency virus (HIV)-1 LTR promoter. Here, we demonstrate that the knockdown of
endogenous CBF-1 in latently infected primary CD4+ T cells, using specific small hairpin RNAs
(shRNA), resulted in the reactivation of latent HIV proviruses. Chromatin immunoprecipitation
(ChIP) assays using latently infected primary T cells and Jurkat T-cell lines demonstrated that CBF-1
induces the establishment and maintenance of HIV latency by recruiting polycomb group (PcG/PRC)
corepressor complexes or polycomb repressive complexes 1 and 2 (PRC1 and PRC2). Knockdown of
CBF-1 resulted in the dissociation of PRCs corepressor complexes enhancing the recruitment of RNA
polymerase II (RNAP II) at HIV LTR. Knockdown of certain components of PRC1 and PRC2 also led
to the reactivation of latent proviruses. Similarly, the treatment of latently infected primary CD4+
T cells with the PRC2/EZH2 inhibitor, 3-deazaneplanocin A (DZNep), led to their reactivation.
Keywords: HIV-1; latency; epigenetics; CBF-1; PRC1; PRC2; chromatin; transcription

1. Introduction
The anti-human immunodeficiency virus (HIV) therapy, ART, has been highly successful in
controlling human immunodeficiency virus (HIV) replication and maintaining the level of circulating
HIV below the limit of detection. However, interruption of ART, even after decades of successful
anti-HIV therapy, results in rapid and robust viral rebound [1–3]. The failure of ART to eradicate HIV
is due to the creation of stable reservoirs of latently infected cells harboring slowly or non-replicating
viruses. The majority of latent proviruses reside in resting memory CD4+ T cells, which provide
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a stable pool of latently infected cells with half-life roughly around 44 months [4–6]. These latent
reservoirs are frequently replenished due to both the homeostatic proliferation of latently infected cells
and the ectopic reactivation of latent proviruses followed by new rounds of infection, presumably
owing to locally sub-optimal ART concentrations [7–10]. It is now well established that ART alone
cannot eradicate latently infected cells, since the intensification of ART was also found to be ineffective
in reducing latent reservoir [8,11]. Hence, developing therapeutic interventions with a focus on HIV
eradication will require the precise definition of the molecular mechanisms responsible for both the
establishment and maintenance of HIV latency, in order to either reactivate latent proviruses, so that
they can be destroyed, or fossilize them forever like human endogenous retroviruses (HERVs).
As a retrovirus, the HIV replication depends on efficient transcription. HIV transcription primarily
relies on the availability of the host cell transcription machinery, along with HIV’s own master
transactivator protein Tat. Inefficient proviral transcription appear to be the major factor contributing
to HIV latency. Numerous factors and multiple mechanisms are known to impair HIV transcription,
and thus shown to promote HIV latency [9,12–14]. Notably, the type of epigenetic modifications and
the resultant state of chromatin structures at the integrated HIV provirus provides critical signals
that regulate transcription during both productive and latent HIV infections [9,15–17]. The role of
repressive epigenetic modifications in supporting HIV latency is quite evident by the fact that their
removal or inhibition leads to the reactivation of latent proviruses [15,18,19].
We previously described the important role of C-promoter binding factor-1 (CBF-1), a CSL
(CBF-1, SuH and Lag-1) type transcription factor, in restricting HIV transcription during HIV
latency [20]. CBF-1 is a key effector of Notch signaling pathways, which play a critical role in
several developmental processes [21]. CBF-1 restricts the expression of several cellular genes that
carry appropriate DNA-binding sites for CBF-1 by recruiting histone deacetylases (HDACs) containing
corepressor complexes [20,22,23]. By performing experiments in both transformed and primary CD4+
T cells, we have established the role of CBF-1 as a potent repressor of HIV transcription [20,24]. We have
demonstrated that CBF-1, after binding to specific sites in HIV LTR, recruits corepressor complexes
containing HDACs (HDAC1 and HDAC3). HDACs subsequently deacetylate the core histones and
facilitate the establishment of transcriptionally repressive heterochromatin structures at HIV LTR.
The closed/compact heterochromatin structures restrict the flow of transcriptional machinery at LTR
promoter and thus hamper HIV transcription and promote HIV latency [20,24].
The recent literature suggests that CBF-1 restricts cellular gene expression, not only through histone
deacetylation, but also by inducing numerous other repressive epigenetic modifications, including
the trimethylation of histone H3 at positions lysine 9 (H3K9me3) or lysine 27 (H3K27me3) [25–27].
The presence of H3K9me3 and H3K27me3 at LTR and their role in establishing heterochromatin during
HIV latency have already been demonstrated, both by us and others [20,28–31]. In addition, we
have also validated their physiological significance by showing the role of these repressive epigenetic
modifications in establishing HIV latency in primary CD4+ T cells [24]. The formation of H3K9me3 is
primarily catalyzed by two methytransferases, namely SUV39H1 and G9A [32]. The methylation of
histone H3 at position 27 (H3K27me3) is mainly catalyzed by EZH2 and occasionally by EZH1 [33–36].
EZH2 and EZH1 are the main catalytic components of the PRC2 complex [37,38]. SUV39H1 and G9A
frequently interact with different components of PRC1 complex [39,40]. PRC1 complex primarily
inhibits transcriptional elongation via the monoubiquitination of histone H2A, but it is also involved
in several other epigenetic transactions along with the PRC2 complex via different interactions among
their subunits [38,41,42]. PRCs play an important role in both inducing and maintaining the silencing
of several cellular genes. PRCs restrict cellular gene expression by simultaneously inducing various
types of repressive epigenetic modifications involving both histones and DNA, as PRCs carry multiple
chromatin modifying enzymes [38,43–47]. Consequently, PRCs-mediated epigenetic modifications
regulate not only the transient gene silencing, but also the long-term silencing of the genes, such as of
Hox genes and X-chromosome inactivation [48–51].
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In this study, we show that CBF-1 is the factor that promotes the recruitment of PRCs at HIV LTR.
Recently, the role of PRCs during both the establishment and maintenance phases of HIV latency was
confirmed, and the presence of H3K27me3 at HIV LTR was documented [52–56]. We further established
the physiological significance by showing the role of H3K27me3 during HIV latency in primary CD4+
T cells [24]. However, the identity of the factor that recruits PRCs at HIV LTR was obscure. Remarkably,
most of the enzymes that catalyze epigenetic modifications are not able to bind directly to the DNA,
and thus need to be recruited to DNA templates by various DNA binding proteins. Proteins such
as CBF-1, YY1/LSF1, P50 homodimer, AP4, CTIP2, and thyroid hormone receptor recruit chromatin
modifying enzymes in the form of multiprotein corepressor complexes to HIV LTR [20,30,57–60]. Using
latently infected primary CD4+ T cells, we found that CBF-1 is the protein that recruits both PRC1
and PRC2 at HIV LTR. We confirmed that, by recruiting PRCs at HIV LTR, CBF-1 supports both the
establishment and maintenance of HIV latency. Furthermore, we validated the direct role of PRCs in
HIV latency, as their knockdown results in the reactivation of latent HIV.
2. Materials and Methods
2.1. Cell Culture, Cell Lines, Antibodies and Chemicals
The CD4+ T cells were isolated, either from tonsils obtained from routine tonsillectomy or from
peripheral blood mononuclear cells (PBMCs) of healthy donors, using Ficoll–Hypaque (GE Healthcare,
Chicago, IL, USA) gradient centrifugation. CD4+ T cells were purified by negative selection method
using a MACS kit (Miltenyi Biotechnology, Auburn, CA, USA). CD4+ primary T cells and H80 cells
were maintained in RPMI 1640 medium, supplemented with 10% fetal calf serum and 25 mM HEPES.
CD4+ primary T cells were supplemented with recombinant human IL-2 (20 U/mL) (R&D Systems,
Inc., Minneapolis, MN, USA). 293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum. T-cell lines CEM and Jurkat were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 IU/mL), and streptomycin
(100 µg/mL). All cells were grown at 37 ◦ C, and in the presence of 5% CO2 . Several of the antibodies
were purchased from Santa Cruz, including anti-RNA polymerase II (RNAP II) (N-20 sc-899; F-12
sc-55492; A-10 sc- 17798), CBF-1 (Millipore, Burlington, MA, USA, AB5790; E-7 sc-271128; Sigma, Louis,
MO, USA, AB384), CIR (C-19; H-1, sc-514120), mSIN3A (AK-11, G-11 sc-5299), HDAC-1 (H-51 sc-7872;
H11 sc-8410, 10E2 sc-81598), HDAC-3 (H-99 sc-11417; A-3 sc-376957), p300 (C-20 sc-585; F-4 sc-48343),
HP1α (C15 sc-10210; Active Motif 2HP-1H5).GAPDH (6C5 sc-32233; 0411 sc-47724), anti-β-actin
(C-4 sc-47778), Spt5 (D-3 sc-133217), EED (H-300 sc-28701; Active Motif 41D) and p65 (F-6 sc-8008);
Preimmune Rabbit IgG control (Cell Signaling, Danvers, MA, USA, #2729S), anti-phospho-Ser2 RNAP
II (Active Motif 3E10; Abcam ab5095), acetyl-histone H3 (Upstate 07-593); SUZ12 (Cell Signaling,
3737S); EZH2 (Cell Signaling 5246S; Millipore 17-662); JARID1A (Abcam, ab65769); H3K9me3 (Upstate
07-442, Abcam ab8898-100); H3K27me3 (07-449; Upstate); RING1B (Active Motif 39663); BMI1(Active
Motif AF27, Upstate F6). We also procured TNF-α (R&D systems), 3-deazaneplanocin A (DZNep,
Cayman), α-CD3/CD28 antibodies conjugated to magnetic beads (Dynal Biotech, Oslo, Norway), and
IL-2 (R&D Systems, Inc.).
2.2. HIV Lentiviral Vectors and Generation of VSV-G-Pseudotyped Viral Particles
The HIV-1-based lentiviral vectors pHR0 P-PNL-mCherry and pHR0 P-PNL-d2EGFP were
constructed with either wild-type Tat or defective H13L Tat as described previously [20].
The construction of pHR0 -PNL-Luc has also been previously detailed [20]. The small hairpin RNAs
(shRNA) vector pHR0 P-SIN-CMV-GFP was generated by cloning the CMV-GFP insert into the SacII
to XhoI sites of the pHR0 P-SIN-18 vector. The short hairpin RNA (shRNA) inserts were initially
cloned into the pSuper vector (Oligoengine). The shRNA plus the H1 promoter were then cloned into
pHR0 P-SIN-CMV-GFP between the BamH1 and SalI sites, as detailed earlier [20,61]. The HIV-based
lentiviral vector particles pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G) were
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produced using a three-plasmid co-transfection procedure [62,63]. The viruses were concentrated by
ultracentrifugation, aliquoted and frozen at −80 ◦ C until use.
2.3. Tyagi-Sahu Model to Generate Latently Infected Primary CD4+ T Cells
The latently infected primary CD4+ T cells were generated using our well established Tyagi–Sahu
model system [24,64]. Briefly, the purified CD4+ T cells (>98% pure) from either PBMCs or tonsils
were stimulated for 4 days with 25 µL of α-CD3/-CD28 antibodies conjugated to magnetic beads
(Dynal Biotech) per million cells, along with 20 U/mL of IL-2. One million cells were infected with
one of the VSV-G-pseudotyped HIV viruses expressing fluorescent protein gene through HIV LTR
promoter. After 2 to 4 days, the fluorescent cells were purified by fluorescence-activated cell sorting
(FACS). The pure population of infected cells was again amplified in the presence of α-CD3/-CD28
antibody-conjugated Dynal beads (25 µL/106 cells) and 20 U/mL of IL-2 for 2 to 3 weeks. Fresh medium
was added every 4 days to maintain a density of 1.5 × 106 to 2.0 × 106 cells/mL. Once it became 0.5 × 108
to 1 × 108 , the cells were placed on 30% to 40% confluent H80 adherent cell mono-layer [24,64]. Every
2 to 3 days, half of the culture medium was replaced by fresh IL-2-containing medium, and every 2
weeks, the T lymphocytes were transferred to the fresh flasks of H80 feeder cells. Once most of the
cells (>95%) lost GFP, we reactivated a fraction of cells via T cell receptor (TCR) stimulation by treating
them with α-CD3/-CD28 antibody-conjugated Dynal beads (25 µL/106 cells) and 20 U/mL of IL-2.
Once we confirmed that most of the cells carry transcriptionally silent (latent HIV), we characterized
the cells as detailed previously [24] and (Supplementary Figure S1). Those latently infected primary
CD4+ T cells were then utilized in assays, before and after reactivating the latent provirus via TCR
stimulation [24,64].
2.4. ChIP Assays and q-PCR
Chromatin immunoprecipitation (ChIP) assays were done following a previously described
protocol [20,24]. To activate cells, we used either 10 ng/mL TNF-α (for cell lines) or 25 µL per 106
cells of α-CD3/CD28 antibodies bound Dynal beads, along with 20 U/mL of IL-2 (for primary T cells).
The chromatin was immunoprecipitated using different antibodies detailed in the antibodies section.
Each sample (5%) was analyzed by quantitative real-time PCR (qPCR) to assess the amount of
sample immunoprecipitated by an individual antibody. SYBR green PCR master mix (12.5 µL/sample;
Bio-Rad, Hercules, CA, USA) combined with 1 µL of each primer, 5 µL of ChIPed DNA and water
to a final volume 25 µL was analyzed by real-time q-PCR. The primers used were the following
(numbered with respect to the transcription start site): promoter region of HIV-1 LTR (promoter)
forward,−116, AGCTTGCTACAAGGGACTTTCC and reverse +4, ACCCAGTACAGGCAAAAAGCAG;
nucleosome-1 region HIV-1 LTR (Nuc-1) forward +30, CTGGGAGCTCTCTGGCTAACTA
and reverse +134,
TTACCAGAGTCACACAACAGACG; glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) promoter forward, −125, CACGTAGCTCAGGCCTCAAGAC and
reverse, −10, AGGCTGCGGGCTCAATTTATAG; GAPDH was also assessed by forward, −145,
TACTAGCGGTTTTACGGGCG and reverse, +21 TCGAACAGGAGGAGCAGAGAGCGA.
2.5. Western Blotting
Western blotting was performed according to standard protocols. Briefly, nuclear extracts were run
on acrylamide Tris-HCl buffered SDS-PAGE gels (7.5% to 10%). Gels were wet transferred using 20%
methanol onto nitrocellulose membranes. Membranes were blocked for one hour at room temperature
in 5% non-fat milk blocking buffer. Primary antibodies were diluted with 1% non-fat milk in 1× TBST
and incubated overnight at 4 ◦ C. Washes were performed with TBS 0.1%Tween-20 (TBST) before the
addition of secondary antibody for 1 h at room temperature. Washes were performed with 1× TBST,
and the protein detection was performed using Odyssey Infrared imaging system (application software
version 3.0.30). Details of primary antibodies are described in Section 2.1.
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2.6. Luciferase Assays
Cells in 6-well plates were harvested after 48 h of treatment, washed twice in phosphate-buffered
saline (PBS), and then lysed in 100–200 µL of 1× Passive Lysis Buffer (Promega, Madison, WI, USA) for
30 min at room temperature (RT). The firefly luciferase activity was analyzed by luciferase reporter
assay system (Promega) and normalized by protein concentration of cell lysate.
2.7. Transfection
For generating vesicular stomatitis virus G-pseudotyped HIVs, the 293T cells were transfected
with plasmids using lipofectamine (Invitrogen/ThermoFisher Scientific, Waltham, MA, USA), applying
a previously described methodology [62,63]. The viral titer was determined by the infection of 1 × 106
Jurkat T cells with serial dilutions of the harvested culture supernatant. However, for the transfection
of small interfering RNA (siRNA), we used lipofectamine RNAiMAX (Invitrogen/ThermoFisher
Scientific), according to the manufacturer’s protocols. For each gene, 4 siRNA target sequences
(20 nM each) were used (Table 1). CBF-1 shRNA constructs: besides using Clone ID TRCN0000016204,
TRCN0000016203 (Open Biosystems), we also used the following shRNA sequences to clone in a
lentiviral vector, and expressed through H1 promoter. As control, cells were either infected with
lentiviral vector expressing scrambled shRNA or transfected with a neutral scrambled siRNA sequence.
Briefly, the cells were incubated with lipofectamine RNAiMAX reagent and siRNA in opti-MEM
medium (Invitrogen/ThermoFisher Scientific) at RT for 5 to 7 min. Subsequently, siRNA-lipid complex
was added to the cells and incubated for 48 h at 37 ◦ C in cell culture incubator. Three independent
experiments were performed (error bars = SD; n = 3). The knockdown effects were assessed by Western
blotting using respective antibodies.
Table 1. List of sequences of siRNA, shRNA and constructs.
Name of Target Gene

Sequence (50 -30 )
GCTGACAATCAAATGAATCAT

SUZ12

CCAAACCTCTTGCCACTAGAA
GCTTACGTTTACTGGTTTCTT
CGAAACTTCATGCTTCATCTA
GACACTCTGGTGGCAATATTT

EED

CCTATAACAATGCAGTGTATA
GTGCGATGGTTAGGCGATTTG
CTGGATCTAGAGGCATAATTA
CGGCTCCTCTAACCATGTTTA

EZH2

CCCAACATAGATGGACCAAAT
GCTGACCATTGGGACAGTAAA
CAACACAAGTCATCCCATTAA
ATTGATGCCACAACCATAATA

BMI1

GGAACCTTTAAAGGATTATTA
CAGCAAGTATTGTCCTATTTG
TAATGGATATTGCCTACATTT

Scrambled

TTGATGCACTTACTAGATTAC

2.8. Flow Cytometry
The expression of fluorescent reporter gene was assessed through fluorescence-activated cell
sorting (FACS) using a FACS Calibur flow cytometer. At 48 h post-stimulation via α-CD3/-CD28
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antibody along with IL-2, the expression of fluorescent protein was assessed. The mixed populations
were sorted by flow cytometry to enrich 100% HIV-infected cells based on fluorescent protein expression.
The shutting down process of latently infected cells to become latent was assessed by flow cytometry
every other week [24]. The presence of latent provirus was confirmed by activating the latently infected
cells with α-CD3/-CD28 antibody along with IL-2 for roughly 50 h. For some experiments, in order
to analyze cells afterword, the cells were fixed with 3% formaldehyde and stored at 4 ◦ C before
flow cytometry.
2.9. Cell Cytotoxicity: MTS Assay
The cytotoxicity of EZH2, inhibitor DZNep in Jurkat, carrying pHR’-PNL-Luc, was assessed using
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
reagent (Promega), following the supplier’s protocol. Briefly, the cells were seeded (3 × 103 cells/well) in
96-well plates and incubated with increasing concentrations of DZNep for 2 days. Then, the cells were
incubated for 4 h with the MTS reagent directly added in the culture wells. Subsequently, the optical
density was measured at 490 nm, using a visible light 96-well plate reader.
2.10. Statistical Analysis
Data were analyzed using Microsoft Excel or GraphPad Prism 5.0 (GraphPad Software, San Diego,
CA, USA). For paired samples, statistical analyses were performed using Student’s t test. One-way
analysis of variance (ANOVA) was performed for multiple data point comparisons. Experimental data
are presented as the mean ± SD of at least three independent experiments. p < 0.05 was considered
significant: p values were defined as * p < 0.05, ** p < 0.01 and *** p < 0.001.
3. Results
3.1. CBF-1 Knockdown Disrupts the Latency Maintenance and Leads to the Proviral Reactivation in Primary
T Cells
We have already confirmed the important role of CBF-1 during the establishing phase of HIV
latency, including in primary CD4+ T cells [20,24]. There is an inverse correlation between cellular
levels of CBF-1 and HIV gene expression. Accordingly, cells harboring latent provirus have higher
levels of CBF-1. However, upon cell activation, we observed a sharp decline in the cellular levels
of CBF-1 and a corresponding reactivation of latent provirus. Moreover, using Jurkat cells, a T cell
line, the important role of CBF-1 during the maintenance phase of HIV latency was illustrated
(Supplementary Figure S2) [20]. In order to extend those studies and further define the role of CBF-1
in primary CD4+ T cells during latency maintenance, we performed some knockdown experiments.
We knocked down the endogenous CBF-1 in physiologically relevant primary CD4+ T cells carrying
latent provirus, and the reactivation of latent provirus was assessed. The rationale behind doing
these experiments was that, if CBF-1-imposed transcriptional restrictions play an essential role in
maintaining HIV latency, then its removal should relieve those restrictions and lead to proviral
reactivation. The latently infected primary CD4+ T cells harboring pHR’-PNL-Luc HIV provirus, which
expresses luciferase as reporter through LTR promoter (Figure 1a), were generated using established
methodology [20,24].
To knockdown endogenous CBF-1, the latently infected primary cells were superinfected with
lentiviral vectors expressing shRNAs either against CBF-1, or control scrambled shRNA. Scrambled
shRNA was confirmed for its neutrality towards HIV and cellular genomes using the NCBI program
Blast [20]. More than 70% knockdown (** p < 0.01) was obtained using 4 µg of shRNA vectors
(Figure 1b,c). Depletion of CBF-1 resulted in significant reactivation of latent provirus (** p < 0.01),
indicated by the enhanced expression (more than three-fold) of luciferase reporter gene compared
to a scrambled shRNA control and unstimulated cells (Figure 1d). As positive control to show the
population of cells carrying reactivable latent provirus in their genome, cells were activated through
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T cell receptor (TCR) stimulation by treating the cells with anti-CD3/-CD28 antibodies in the presence
of
IL-22019,
(α-CD3/CD28/IL-2).
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3.2. CBF-1 Recruited PRCs Play Direct Role in Sustaining HIV Provirus in Latent State
In order to establish the direct role of the PRCs in controlling HIV latency, we knocked down
In order to establish the direct role of the PRCs in controlling HIV latency, we knocked down
the core components of both PRC1 and PRC2. Subsequently, we examined whether the removal of
the core components of both PRC1 and PRC2. Subsequently, we examined whether the removal of
repression posed by PRCs on HIV transcription leads to the reactivation of the latent HIV proviruses.
Jurkat cells harboring latent HIV provirus pHR’-PNL-Luc, a lentiviral vector carrying the luciferase
reporter gene under the control of the HIV LTR (Figure 1a), were used. The cells were transfected
with the 20 nM siRNA against main components of PRCs (PRC1 and PRC2). We used a mixture of

of the components of PRC2 was slightly more effective than PRC1 subunits in reactivating latent
proviruses. A similar effect with the knockdown of each target gene suggested the removal of any of
the core component of PRCs destabilizes the corepressors complex at LTR.
Similar results were obtained when we disabled the PRC2 complex by inhibiting the EZH2 using
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DZNep,
histone methylation inhibitor. DZNep is known to downregulate
cellular levels of several histone methylases, mainly EZH2 [66]. Latently infected Jurkat cells
harboring the latent HIV provirus, pHR’-PNL-Luc, were treated dose-dependently with DZNep (2
repression posed by PRCs on HIV transcription leads to the reactivation of the latent HIV proviruses.
μM to 32 μM). After 48 h, cell extracts were assessed for the activity of luciferase enzyme by
Jurkat cells harboring latent HIV provirus pHR’-PNL-Luc, a lentiviral vector carrying the luciferase
performing luciferase assays. As anticipated, the inhibition of PRC2 by DZNep led to proviral
reporter gene under the control of the HIV LTR (Figure 1a), were used. The cells were transfected with
reactivation (** p < 0.01), which further validates the vital role of PRC2 in promoting HIV latency
the 20 nM siRNA against main components of PRCs (PRC1 and PRC2). We used a mixture of four
(Figure 2c). Additionally, these results were further reproduced in another latently infected T cell line
siRNAs (20 nM each) against each target gene, and the non-targeting scrambled siRNA was used as
(2D10 cells), which expresses GFP as reporter (Supplementary Figure S3).
control. When compared with scrambled control, a significant knockdown of more than 70% (** p < 0.01)
To exclude the possibility that the loss of luciferase activity was due to non-specific cell
was evident for each target gene (Figure 2a). The reactivation of latent provirus was assessed through
cytotoxicity of DZNep (EZH2 inhibitor), cells were treated with increasing dose of inhibitor and cell
luciferase reporter assay. Around three-fold reactivation of latent provirus was observed following
viability was assessed using a MTS assay. We did not find any significant cell cytotoxicity up to the
knockdown of each component of PRCs (** p < 0.01) (Figure 2b). Notably, the knockdown of the
dose of 32 μM even after 5 d in culture (Supplementary Figure S3a). More than three-fold proviral
components of PRC2 was slightly more effective than PRC1 subunits in reactivating latent proviruses.
reactivation was observed at concentrations of 8 μM and beyond. At doses higher than 8 μM, little
A similar effect with the knockdown of each target gene suggested the removal of any of the core
proviral reactivation was observed (Supplementary Figure S3b,c). These results further corroborated
component of PRCs destabilizes the corepressors complex at LTR.
the direct role of PRCs in restricting the transcription of latent HIV provirus.
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DZNep treatment. (a) Western blot showing the efficiency of siRNA to knockdown indicated subunits
treatment. (a) Western blot showing the efficiency of siRNA to knockdown indicated subunits of
of PRCs. The densitometry analyses were then represented graphically after normalization to actin.
Quantitative luciferase assays marking proviral reactivation either after (b) knockdown of individual
subunits belonging to PRCs or (c) upon DZNep treatment (from 2 µM to 32 µM) of cells. Graphs
represent the average and standard deviation from three independent and replicate samples. Statistical
analysis was done using Microsoft Excel and GraphPad Prism 5.0 (GraphPad Software, San Diego, CA,
USA). The p value of statistical significance was set as: p < 0.01 (**).

Similar results were obtained when we disabled the PRC2 complex by inhibiting the EZH2 using
DZNep, a broad-spectrum histone methylation inhibitor. DZNep is known to downregulate the cellular
levels of several histone methylases, mainly EZH2 [66]. Latently infected Jurkat cells harboring the
latent HIV provirus, pHR’-PNL-Luc, were treated dose-dependently with DZNep (2 µM to 32 µM).
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After 48 h, cell extracts were assessed for the activity of luciferase enzyme by performing luciferase
assays. As anticipated, the inhibition of PRC2 by DZNep led to proviral reactivation (** p < 0.01),
which further validates the vital role of PRC2 in promoting HIV latency (Figure 2c). Additionally, these
results were further reproduced in another latently infected T cell line (2D10 cells), which expresses
GFP as reporter (Supplementary Figure S3).
To exclude the possibility that the loss of luciferase activity was due to non-specific cell cytotoxicity
of DZNep (EZH2 inhibitor), cells were treated with increasing dose of inhibitor and cell viability was
assessed using a MTS assay. We did not find any significant cell cytotoxicity up to the dose of 32 µM
even after 5 d in culture (Supplementary Figure S3a). More than three-fold proviral reactivation was
observed at concentrations of 8 µM and beyond. At doses higher than 8 µM, little proviral reactivation
was observed (Supplementary Figure S3b,c). These results further corroborated the direct role of PRCs
in restricting the transcription of latent HIV provirus.
3.3. CBF-1 Promotes HIV Latency by Inducing Multiple Types of Repressive Epigenetic Modifications at
HIV LTR
In earlier publications, we demonstrated that CBF-1 restricts HIV transcription by recruiting
HDACs containing corepressor complexes at HIV LTR. HDACs subsequently mediate the deacetylation
of core histones, eventually facilitating the establishment of HIV latency, both in transformed and
primary CD4+ T cells [20,24]. Since various corepressor complexes contain HDACs, a goal was to
define the precise identity of the corepressor complex recruited by CBF-1 at HIV LTR during HIV
latency. In addition to histone deacetylation, numerous studies including ours have established the
importance of other repressive epigenetic modifications, such as the tri-methylation of core histone
H3 at position 9 (H3K9me3) and 27 (H3K27me3) during HIV latency [9,20,24,28,29,67]. The role of
enzymes responsible for catalyzing these epigenetic modifications during HIV latency has also been well
documented [28–31,52,68]. We have also confirmed the role of H3K9me3 and H3K27me3 in primary
CD4+ T cells during HIV latency [24]. We investigated whether CBF-1-recruited corepressors are
responsible for inducing those repressive histone H3 methylations and promoting HIV latency. In order
to determine whether CBF-1 is responsible for inducing varying repressive epigenetic modifications,
we assessed the impact of CBF-1 knockdown on the resultant epigenetic changes at HIV LTR. If the
enzymes present in the CBF-1 recruited corepressor complex are responsible for catalyzing H3K9me3
and H3K27me3 modifications, then CBF-1 knockdown should result in the reduced recruitment of the
corepressor complex and thus, less generation of H3K9me3 and H3K27me3 at HIV LTR.
To investigate this latently infected Jurkat T cell line, a clone E4, in which the Nef gene is replaced
by a short lived green fluorescent protein (d2EGFP) reporter, was used [20,31]. The latently infected
cells were superinfected with lentiviral vectors carrying shRNAs, either against CBF-1 or control
scrambled shRNA, a target neutral sequence. The cellular population carrying shRNA vectors was
enriched via puromycin selection.
To assess the binding of different transcription and epigenetic factors, besides changes in
corresponding epigenetic modifications at HIV LTR in the absence or presence of CBF-1 knockdown,
quantitative ChIP assays were performed, and the two critical regions of HIV LTR, promoter (Figure 3a)
and nucleosome-1 (Nuc-1) (Figure 3b) were examined. The immunoprecipitated DNA was measured
through q-PCR using primer sets directed to the promoter region (−116 to +4) and nucleosome-1
region (+30 to +134) of LTR with respect to the transcription start site. To provide a control for equal
loading, the results were normalized with housekeeping GAPDH gene expression (−145 to +21),
a constitutively expressed cellular gene. Latently infected Jurkat cells showed low levels of RNAP II at
both the promoter and Nuc-1 regions of LTR (Figure 3). Given ChIP resolution capacity of ~500 bp
due to DNA shearing limit during sonication, we found overlapping signals at the promoter and
neighboring Nuc-1 regions of LTR. Nevertheless, histone modifications were clearly more prevalent at
the histone-rich Nuc-1 region (Figure 3b).
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(Supplementary Figure S4). We also found the presence of JARID1A at HIV LTR. JARID1A is a
histone H3K4me3 demethylase, which removes the methyl group from histone H3 at position 4
(H3K4me3), a euchromatic mark. At cellular promoters, JARID1A has been shown to interact with
both CBF-1 and its recruited corepressor complexes, including PRCs [25,74,75]. The accumulation of
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mark. At cellular promoters, JARID1A has been shown to interact with both CBF-1 and its recruited
corepressor complexes, including PRCs [25,74,75]. The accumulation of epigenetic modifications,
such as H3Ac and H3K4me3 supports the establishment of transcriptionally active or euchromatin
structures. We found that JARID1A and HDACs of PRCs remove these pro-euchromatin modifications
(H3K4me3 and H3Ac) at HIV LTR. Therefore, besides harboring the enzymes that induce the formation
of transcriptionally repressive heterochromatin structures, PRCs also carry the enzymes which remove
the euchromatin structures, consequently supporting prolonged or permanent gene silencing. Hence,
by recruiting PRCs at HIV LTR, CBF-1 not only facilitates the establishment of HIV latency, but also
promotes the maintenance or stabilization of HIV latency. This conclusion is also supported by the
observation that when we knockdown the endogenous CBF-1, the latent provirus gets reactivated
(Figure 1). Thus, by recruiting PRCs at HIV LTR, CBF-1 induces multiple layers of repressive epigenetic
modifications to form transcriptionally repressive heterochromatin structures at HIV LTR during HIV
latency. Consequently, CBF-1 not only promotes, but also stabilizes the silencing of latent proviruses.
3.5. CBF-1 Recruited PRCs Facilitate HIV Latency in Primary CD4+ T Cells
Like an ideal repressor of HIV transcription, CBF-1 is present in abundant amounts in resting
T cells. However, upon cell activation, CBF-1 levels drop sharply, a property also visible in Figure 1b,c.
This unique characteristic of CBF-1 has been confirmed in different cell types [20]. This implies that after
cell activation, reduced cellular levels of CBF-1 result in poor recruitment of CBF-1 at LTR. In parallel,
if CBF-1 contributes to the recruitment of PRCs at LTR, then we envisioned proportionally reduced
recruitment of PRCs at LTR.
Thus, to validate our hypothesis and provide physiological relevance to these findings,
we performed ChIP assays using latently infected primary CD4+ T cells (Figure 5). The latently
infected primary CD4+ T cells, harboring either pHR’-PNL-H13LTat-mCherry (Figure 5a–c),
pHR’-PNL-wildTat-mCherry (Figure 5d,e) or pHR’-PNL-H13LTat-d2GFP (Figure 5), were generated
using Tyagi-Sahu primary T cell based latency model, described earlier [24,64] (Supplementary
Figure S1a). These HIV-derived vectors (Figure 5a) express fluorescent protein reporter genes (either the
short-lived d2EGFP or mCherry) in place of the nef gene, as detailed earlier [20,24,31]. These viruses
express the regulatory proteins Tat and Rev. Like complete HIV, the positive feedback circuit that
enhances HIV transcriptional elongation and export of mRNA from the nucleus is fully intact. In some of
our experiments, in order to increase the frequency of latently infected cells in the population, we utilized
Tat carrying the H13L mutation. This partially attenuated Tat variant was originally identified in the
U1 latently infected cell line and is highly prevalent in latent proviral pools of HIV patients [76,77].
Quantitative ChIP assays were performed before and after activating the latently infected primary
CD4+ T cells with α-CD3/-CD28 antibodies in the presence of IL-2 for 30 min. The immunoprecipitated
DNA was measured through q-PCR, using primer sets directed to the promoter region (−116 to +4)
and nucleosome-1 region (+30 to +134) of LTR, with respect to the transcription start site. Binding of
different transcription factors and epigenetic changes at these regions of LTR dictate the overall rate
of HIV transcription. As a control for equal loading in each well, the results were normalized with
GAPDH gene expression (−145 to +21), a constitutively expressed cellular gene.
As depicted in Figure 5, lower levels of RNAP II were present at the promoter and Nuc-1 regions
of latent provirus, validating highly restricted gene expression from LTR promoter of latent provirus.
However, in the case of cells infected with provirus carrying wild-type Tat, we observed comparatively
higher levels of RNAP II (Figure 5d,e). The reason behind this anomaly is that this cell population
consists of around 70% latently infected cells (Figure 5d,e), compared to around 95% latently population
in the case of cells infected with provirus carrying H13L Tat (Figure 5b,c). The overall LTR binding
profiles of different factors were quite comparable in case of cells harboring latent provirus either with
wild-type or H13L Tat. We found higher levels of CBF-1, its binding partner mSIN3A and HDAC-1 and
-3 at latent proviral LTR in primary T cells. In parallel, we found that the LTR of latent HIV contains
stable heterochromatin structures, indicated by the higher presence of histone H3 deacetylation,
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H3K9me3 and H3K27me3. Analogous to transformed T cells, we found higher recruitment of both
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These findings validate the vital role of PRCs during HIV latency in primary T cells. Reduced
levels of RNAP II marks restricted ongoing HIV transcription from LTR. However, TCR stimulation,
a condition that results in reactivation of latent provirus [24], led to a five- to seven-fold increase in
RNAP II levels at both promoter and Nuc-1 regions. Higher recruitment of RNAP II marks enhanced
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These findings validate the vital role of PRCs during HIV latency in primary T cells. Reduced
levels of RNAP II marks restricted ongoing HIV transcription from LTR. However, TCR stimulation,
a condition that results in reactivation of latent provirus [24], led to a five- to seven-fold increase in
RNAP II levels at both promoter and Nuc-1 regions. Higher recruitment of RNAP II marks enhanced
ongoing HIV transcription after TCR stimulation. Concomitantly, we also observed a substantial
loss of CBF-1 and recruited corepressor complex, PRCs, from LTR, indicated by the loss of mSIN3A,
HDAC-1, HDAC-3, EZH2, SUZ12, BMI1 and RING1B (Figure 5). Loss of HDACs from LTR translated
into enhanced acetylation of core histones, indicated by a four to seven-fold increase in the acetylation
of histone H3 present at the LTR. Similar to our previous observations in primary T cells [24], we found
the removal of repressive H3K9me3 and H3K27me3 heterochromatic marks from LTR, recruitment of
histone acetyltransferase, p300 at HIV LTR following TCR stimulation. As noted earlier in primary
T cells [24], we found enhanced recruitment of NF-κB (p65) at the promoter region of LTR, as NF-κB
binding sites reside in that region (data not shown).
Given the ChIP resolution limit of ~500 bp, an overlap of signals between adjacent regions, such
as promoter and Nuc-1, was expected. Therefore, to some extent, we observed similar histone changes
at both LTR regions. Nevertheless, a notable difference in the levels of histone modifications was
clearly visible in the Nuc-1 region of the proviruses. These results are consistent with previous studies
using transformed cell lines, which have shown that the HIV promoter region is relatively devoid of
histones [9,20,24,78,79]. In summary, these results have shown that CBF-1 restricts HIV transcription
by recruiting both PRC1 and PRC2 during HIV latency in primary CD4+ T cells. We thus validated the
role of CBF-1 and PRCs during both the establishment and the maintenance of HIV latency in primary
CD4+ T lymphocytes.
4. Discussion
In our previous studies, we demonstrated that CBF-1, after binding to its cognitive sites at HIV LTR,
strongly and selectively represses HIV transcription. In this paper, we show that CBF-1 promotes the
establishment and maintenance of HIV latency by recruiting Polycomb corepressor complexes at HIV
LTR. The polycomb group (PcG) proteins are divided in the form of two main corepressor complexes,
PRC1 and PRC2 [80], that we showed to be present at the HIV LTR. PRCs, by inducing transcriptionally
repressive epigenetic modifications, facilitate the assembly of heterochromatin structures at HIV LTR.
The PRC1 complex mainly catalyzes the monoubiquitination of histone H2A at lysine 119 residue
(H2AK119Ub1) through its Ring subunits, Ring1A/B, which contain E3 ligase activity a [41,81,82].
On the other hand, PRC2 is primarily characterized by the presence of the histone methyltransferases
EZH1/2, which, along with other subunits, mainly SUZ12 and EED, catalyze the di- or trimethylation
of histone H3 at lysine 27 (H3K27me2/3) [34,82]. Given the fact that CBF-1 expression is strongly
reduced following T-cell activation, it is expected that TCR activation in CD4 T-cells should reflect the
results obtained after CBF-1 knockdown. In our previous investigations, we showed the important
role of CBF-1 during HIV latency, by performing experiments in transformed T cell lines [9,20]. Here,
we have extended those findings and confirmed the significant role of CBF-1 during HIV latency in
physiologically relevant primary CD4+ T cells.
The role of H3K9me3 and H3K27me3 during HIV latency is well established. Moreover, we have
shown the importance of these repressive epigenetic marks during HIV latency in primary CD4+
T cells [24]. The formation of the epigenetic mark H3K27me3 is mainly catalyzed by EZH2 enzyme.
We noted higher levels of EZH2 and deposition of H3K27me3 at the LTR of latent provirus present in
primary T cells. EZH2 is the core component of PRC2, and Karn’s group has convincingly demonstrated
the presence and role of EZH2 and of PRC2 during HIV latency establishment and maintenance [52,54].
These results have been validated by other groups [53,55,83]. However, the identity of the factor(s)
that recruit PRCs at HIV LTR and promote HIV latency were not well defined. Recently, Karn’s group
has demonstrated the role of JARID2 in recruiting PRC2 at HIV LTR [54]. In a similar manner, we have
been investigating the role of CBF-1 as a recruiter of PRCs at LTR. We proposed that, if CBF-1 is
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responsible for the recruitment of PRC2 and EZH2, then CBF-1 reduction at LTR should translate to
the lesser accumulation of PRC2 and of H3K27me3 at HIV LTR. Accordingly, we found the comparable
loss of EZH2 and H3K27me3 from LTR upon CBF-1 knockdown (Figure 3). In later CBF-1 ablation
experiments, we observed the corresponding loss of other core components of PRC2, namely EED
and SUZ12, from LTR (Figures 3 and 4). Altogether, these results confirmed the direct role of CBF-1 in
recruiting PRC2 at HIV LTR during HIV latency.
Upon CBF-1 knockdown, we found a parallel loss of the epigenetic mark H3K9me3, suggesting that
the CBF-1 recruited corepressor complex also carries the enzyme that catalyzes the H3K9me3 epigenetic
modification. Notably, PRC2 does not carry any enzyme that catalyzes H3K9me3, but PRC1 is known
to bring SUV39H1 and G9A along with it [40,70]. SUV39H1 and G9A are the two main enzymes which
catalyze the formation of the epigenetic mark H3K9me3 at nucleosomes. This observation suggested
that, along with PRC2, CBF-1 also brings PRC1 to HIV LTR for the generation of transcriptionally
repressive heterochromatin structures at HIV LTR during viral latency. In fact, we observed a
comparable loss of BMI1 and RING1B, two core components of PRC1, following CBF-1 knockdown in
both T cell line and primary T cells (Figures 4 and 5). The presence of PRC1 at HIV LTR during latency
has also been noted by other investigators [52,54,55]. However, the factor that brings PRC1 at LTR was
not known until our investigation demonstrated that CBF-1 is the cellular protein, which, after binding
to LTR at specific sites, brings both PRC1 and PRC2 to inhibit HIV transcription during HIV latency.
Following CBF-1 knockdown, we observed the parallel loss of Dnmt-3b, a DNA methyltransferase.
Dnmt-3b has been shown as a component of various PRC complexes. This finding further validated
that CBF-1 promotes HIV latency by inducing multiple layers of repressive epigenetic modifications,
via recruiting different PRC complexes at HIV LTR [71–73]. In our earlier investigations, we showed
that, in resting T cells that harbor latent provirus, higher levels of CBF-1 are present. However, upon
cell activation, the cellular level of CBF-1 drops sharply and latent HIV proviruses get reactivated [20].
Thus, CBF-1 acts as an ideal transcriptional repressor which plays a vital role in regulating HIV latency.
Therefore, to further validate that cell activation leads to the decline of cellular CBF-1 levels, we
showed the lesser recruitment of CBF-1 at LTR, and consequently, the loss of PRCs from LTR upon
cell activation.
The physiological relevance of these findings is evident, since they were reproduced in latently
infected primary CD4+ T cells. We validated the presence of PRCs at latent HIV proviruses and
confirmed their removal from HIV LTR upon cell stimulation through TCR induction (Figure 5).
Proviral reactivation was indicated by the higher RNAP II recruitment and confirmed through the
enhanced expression of the reporter gene luciferase. Using latently infected primary CD4+ T cells in
an earlier study, we demonstrated the presence of both H3K9me3 and H3K27me3 at the LTR of latent
provirus, which drops sharply following TCR stimulation [24,82]. Similar to our previous findings, we
noted the presence of components of both PRCs, representing the presence of PRC1 and PRC2 at latent
provirus, which is abruptly dissociated from HIV LTR upon TCR stimulation (Figure 5).
Notably, besides core components of PRCs, we also found the presence of certain interacting
partners or auxiliary factors of PRCs, such as HDACs, mSIN3A and HP1α [38]. These factors either bind
directly to PRCs components or to the induced epigenetic modifications (e.g., H3K9me3 modification
promotes the recruitment of HP1 proteins). Subsequently, to confirm the direct role of PRCs during HIV
latency, we assessed the reactivation of latent provirus after the knockdown of different core components
of PRC1 and PRC2 repressor complexes (Figure 2). If PRCs play a significant role in the silencing of
latent HIV provirus, then their removal or reduction by knockdown should relieve that restriction and
lead to proviral reactivation. Consistent with this idea, upon knockdown of the core components, PRCs
become destabilized, and we observed the two- to three-fold reactivation of latent provirus (Figure 2).
Notably, we observed better proviral reactivation following the knockdown of PRC2 components
than PRC1, suggesting a primary role of PRC2 components in the stability of corepressor complex
recruited by CBF-1. Supporting this observation, it has been documented that PRC2/EZH2-induced
H3K27 methylation promotes the recruitment of PRC1 to target cellular genes, and the disruption of
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PRC2 leads to the loss of PRC1 from chromatin targets, but the other way around is not always that
effective [84]. Interestingly, upon CBF-1 knockdown, we found the corresponding loss of JARID1A, an
enzyme which is known to interact with PRC subunits [25,74]. JARID1A is a histone demethylase that
selectively demethylates the histone H3 at position K4, H3K4me3. In contrast to the above-mentioned
trans-repressive epigenetic changes in H3K9me3 and H3K27me3, the trimethylation of histone H3 at
lysine 4 (H3K4me3) is a euchromatic mark, an epigenetic modification that promotes the establishment
of a transcriptionally active euchromatin structure which supports transcription. Thus, JARID1A,
by removing H3K4me3, inhibits the generation of the euchromatin structure at LTR. Consequently,
certain enzymes that are recruited by PRCs, such as JARID1A and HDACs, remove euchromatic marks,
namely H3K4me3 and acetylation of histones, respectively, to provide stability to gene silencing and
restrict transient gene reactivation. Hence, in addition to promoting the establishment of latency by
recruiting PRCs at HIV LTR, CBF-1 promotes the maintenance or stabilization of HIV latency. Moreover,
the reactivation of latent provirus following CBF-1 knockdown or TCR stimulation further validates the
role of CBF-1 during the maintenance phase of HIV latency. Both CBF-1 knockdown or cell activation
reduce cellular CBF-1 levels. Therefore, when we removed the restriction posed by CBF-1 through
knocking it down or via TCR stimulation, the latent provirus becomes reactivated (Figures 1 and 5).
To summarize our results, we propose a model to depict the role of CBF-1 in restricting HIV
transcription during latency (Figure 6). According to our model, in the absence of transcription
factors such as NF-kB and NFAT in quiescent cells, CBF-1 binds to the specific sites at HIV LTR and
recruits PRCs. Enzymes of the PRCs subsequently induce multiple layers of repressive epigenetic
modifications and remove transcriptionally active epigenetic modifications. These epigenetic changes
subsequently facilitate the generation of transcriptionally repressive heterochromatin structures at
HIV LTR. Heterochromatin structures restrict the free flow of transcription factors at HIV LTR, which
eventually restrict HIV transcription and stabilize restriction. Thus, CBF-1 facilitates the establishment
and maintenance of HIV latency. Following cell activation, the levels of CBF-1 drop, whereas levels
of NF-kB, NFAT, and other transcription factors rise in the nucleus, displacing CBF-1 and PRCs
from LTR. Successively, these factors recruit coactivator complexes at HIV LTR, which then establish
the euchromatin environment at HIV LTR, facilitating the access of transcription machinery at LTR
promoter, and thus leading to the reactivation of latent proviruses. Taken together, our results validated
that CBF-1 suppresses HIV gene expression, by recruiting both PRC1 and PRC2 at HIV LTR. Hence,
we conclude that, by recruiting PRCs, CBF-1 facilitates both the establishment and maintenance phases
of HIV latency.
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Figure 6. Model of CBF-1 functioning. Based on our findings, we propose the following model
for the regulation of HIV latency by CBF-1. The higher levels of CBF-1 and lack of transcription
factors such as NF-kB and NFAT in quiescent cells facilitates the binding of CBF-1 at HIV LTR. CBF-1
after binding to LTR recruits PRCs. PRCs subsequently promote heterochromatin environment at
HIV LTR and inhibit the free flow of transcription machinery, thus facilitating the establishment and
maintenance of HIV latency. Following cellular activation, the levels of CBF-1 drop, but the levels of
NF-kB and NFAT rise in the nucleus, which displaces CBF-1 and corepressor complexes from their
binding sites. Eventually, these factors recruit coactivator complexes at HIV LTR, which then establishes
the euchromatin environment at HIV LTR that facilitate the access of transcription machinery at the
LTR promoter, and thus leads to the reactivation of latent proviruses.

5. Conclusions
In conclusion, our study confirms that CBF-1 promotes both the establishment and maintenance of
HIV latency in primary T cells, by recruiting PRC1 and PRC2 at HIV LTR. From a clinical standpoint, our
findings suggest that for the reactivation of latent proviruses, targeting factors that recruit those enzymes
at HIV LTR, which will result in more profound reactivation of latent provirus than targeting individual
enzymes that induce repressive epigenetic modifications. In fact, the removal of the whole corepressor
complex will relieve multiple repressive epigenetic modifications simultaneously, and could prove to
be a better latency reversing strategy, a prerequisite for viral eradication. Through in vitro studies,
we found that PRC2 complex prefers naked DNA for binding over histone-studded chromatinized
DNA structures [85]. However, DNA rarely presents as naked in vivo, as chromatinization takes place
soon after its synthesis. Thus, our findings suggest that besides direct recruitment of PRC through
CBF-1-PRC subunit(s) interactions, CBF-1 binding may create some necked space in DNA that allows
better recruitment of PRC. This will be the focus of our future investigations.
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